Zepteon
Tom Ransohoff, Strategic Advisor, has over twenty years in the biopharmaceutical industry, in areas ranging from product and technology development to cGMP manufacturing. In addition to his previous leadership roles at Tarpon Biosystems and at BioFlash Partners LLC wher he served as CEO, Mr. Ransohoff is a Senior Consultant with Bioprocess Technology Consultants, a leading biopharmaceutical CMC consulting firm. Mr. Ransohoff's previous experience includes senior positions with business unit and operational responsibility at TranXenoGen, Dyax, Repligen, and Xoma. Mr. Ransohoff has a Bachelor's degree from MIT and a Master's degree from UC-Berkeley, both in Chemical Engineering.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Zepteon
Zepteon, Inc. is a privately held corporation founded in 2012 that has developed first in class chromatography resins capable of separating antibodies with specific sugar structures (nonfucosylated) that are more potent against diseases like cancer. This technology enables more effective therapeutics and can reduce cost and dosing requirements.